Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewith

1. A compound of formula (I):

or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof,

wherein:

Ring A is a piperazinyl optionally substituted with one or more substituents independently selected from halogen, C 1-6 alkyl, OR 1 , CON(R 2 ) 2 , SO 2 (C 1-4 alkyl), N(R 2 )SO 2 (C 1-4 alkyl), —(C 0-3 alkyl)-(C 3-7 cycloalkyl), (non-aromatic heterocyclyl), aryl, heteroaryl, O-aryl, O-heteroaryl, and C(O)aryl; wherein the alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl are optionally substituted with one or more substituents independently selected from halogen, alkyl optionally substituted with one or more of halogen, oxo, amido, and cyano; wherein R 1 is H, C 1-6 alkyl optionally substituted with one or more of halogen, or —(C 0-3 alkyl)-(C 3-7 cycloalkyl); and each R 2 is independently H, or C 1-6 alkyl;

each R is independently C 1-3 alkyl optionally substituted with one or more of halogen, or halogen; and

n is 0, 1, 2, 3 or 4.

2. The compound of claim 1 , wherein the compound is a compound of formula (II):

or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof.

3. The compound of claim 1 , wherein the compound is a compound of formula (III):

or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof.

4. The compound of claim 1 , wherein the compound is a compound of formula (IV):

or a pharmaceutically acceptable salt or tautomer thereof.

5. The compound of claim 4 , wherein the compound is a compound of formula (V):

or a pharmaceutically acceptable salt or tautomer thereof.

6. The compound of claim 4 , wherein the compound is a compound of formula (VI):

or a pharmaceutically acceptable salt or tautomer thereof.

7. The compound of claim 1 , wherein the compound is a compound of formula (VII):

or a pharmaceutically acceptable salt or tautomer thereof.

8. The compound of claim 7 , wherein the compound is a compound of formula (VIII):

or a pharmaceutically acceptable salt or tautomer thereof.

9. The compound of claim 7 , wherein the compound is a compound of formula (IX):

or a pharmaceutically acceptable salt or tautomer thereof.

10. The compound of claim 1 , wherein Ring A is

wherein R e is C 1-6 alkyl, SO 2 (C 1-4 alkyl), —(C 0-3 alkyl)-(C 3-7 cycloalkyl), aryl, heteroaryl or CO-aryl; wherein the alkyl, cycloalkyl, aryl, or heteroaryl are optionally substituted with one or more substituents independently selected from halogen, alkyl optionally substituted with one or more of halogen, oxo, amido, and cyano.

11. The compound of claim 1 , wherein Ring A is substituted with one or more substituents independently selected from halogen, C 1-6 alkyl, OR 1 , CON(R 2 ) 2 , SO 2 (C 1-4 alkyl), N(R 2 )SO 2 (C 1-4 alkyl), —(C 0-3 alkyl)-(C 3-7 cycloalkyl), (non-aromatic heterocyclyl), aryl, heteroaryl, O-aryl, O-heteroaryl, and C(O)aryl; wherein the alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl are optionally substituted with one or more substituents independently selected from halogen, alkyl optionally substituted with one or more of halogen, oxo, amido, and cyano; wherein R 1 is H, C 1-6 alkyl optionally substituted with one or more of halogen, or —(C 0-3 alkyl)-(C 3-7 cycloalkyl); and each R 2 is independently H, or C 1-6 alkyl.

12. The compound of claim 1 , wherein Ring A is substituted with one or more substituents independently selected from F, Cl, Br, CH 3 , CH 2 CH 3 , n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, t-butyl, n-pentyl, isopentyl, CH 2 F, CHF 2 , CF 3 , CH 2 CH 2 F, CH 2 CHF 2 , CH 2 CF 3 , CH(CH 3 )CF 3 , CH 2 CH 2 CF 3 , OH, OCH 3 , OCH 2 CH 3 , O-isopropyl, O-n-propyl, O-n-butyl, O-isobutyl, O-t-butyl, OCF 3 , O-cyclopropyl, O-cyclobutyl, OCH 2 -cyclopropyl, OCH 2 -cyclobutyl, CONH 2 , CONH(CH 3 ), CON(CH 3 ) 2 , SO 2 CH 3 , SO 2 CH 2 CH 3 , SO 2 -isopropyl, cyclopropyl, cyclobutyl, CH 2 -cyclopropyl, CH 2 -cyclobutyl; (non-aromatic heterocyclyl) selected from azetidyl, pyrrolidyl, pyrrolidonyl, isothiazolidyl, isothiazolidine 1,1-dioxidyl, piperidyl, piperazinyl, morpholinyl, 3-oxa-8-azabicyclo[3.2.1]octyl, or 8-oxa-3-azabicyclo[3.2.1]octyl, wherein the heterocyclyl is optionally substituted with one or more substituents independently selected from CH 3 , CH 2 CH 3 , or CF 3 ; phenyl, 0-phenyl or C(O)-phenyl, wherein the phenyl is optionally substituted with one or more substituents independently selected from F, Cl, CH 3 , CN, or CONH 2 ; heteroaryl selected from pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidyl, or benzoisoxazolyl, wherein the heteroaryl is optionally substituted with one or more substituents independently selected from F, Cl, CF 3 , CN, CONH 2 , CONH(CH 3 ) or CON(CH 3 ) 2 ; O-pyridyl, and O-pyrimidyl.

13. The compound of claim 1 , wherein Ring A is substituted with one or more substituents independently selected from F, CH 3 , CH 2 CH 3 , isopropyl, t-butyl, CH 2 F, CF 3 , CH(CH 3 )CF 3 , OH, OCH 3 , OCH 2 CH 3 , O-isopropyl, O-n-propyl, O-isobutyl, O-t-butyl, OCF 3 , O-cyclobutyl, OCH 2 -cyclopropyl, CON(CH 3 ) 2 , SO 2 CH 2 CH 3 , SO 2 -isopropyl, cyclopropyl, cyclobutyl, CH 2 -cyclopropyl; (non-aromatic heterocyclyl) selected from pyrrolidyl, pyrrolidonyl, isothiazolidine 1,1-dioxidyl, morpholinyl, 3-oxa-8-azabicyclo[3.2.1]octyl, or 8-oxa-3-azabicyclo[3.2.1]octyl, wherein the heterocyclyl is optionally substituted with one or more CH 3 ; phenyl, O-phenyl or C(O)-phenyl, wherein the phenyl is optionally substituted with one or more substituents independently selected from F, Cl, CH 3 , CN, or CONH 2 ; heteroaryl selected from pyrazolyl, oxazolyl, oxadiazolyl, thiadiazolyl, pyridyl, pyrazinyl, pyrimidyl or benzoisoxazolyl, wherein the heteroaryl is optionally substituted with one or more substituents independently selected from F, Cl, CF 3 , CN, CONH 2 , CON(CH 3 ) 2 ; O-pyridyl, and O-pyrimidyl.

14. The compound of claim 1 , wherein Ring A is piperazinyl, substituted with one or more substituents independently selected from C 1-6 alkyl, SO 2 (C 1-4 alkyl), —(C 0-3 alkyl)-(C 3-7 cycloalkyl), aryl, heteroaryl and CO-aryl; wherein the alkyl, cycloalkyl, aryl, or heteroaryl are optionally substituted with one or more substituents independently selected from halogen, alkyl optionally substituted with one or more of halogen, oxo, amido, and cyano.

15. The compound of claim 1 , wherein Ring A is piperazinyl, substituted with one or more substituents independently selected from CH 3 , CH 2 CH 3 , n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, t-butyl, CF 3 , CH 2 CF 3 , CH(CH 3 )CF 3 , SO 2 CH 3 , SO 2 CH 2 CH 3 , SO 2 -isopropyl, cyclopropyl, cyclobutyl, (CH 2 )cyclopropyl, (CH 2 )cyclobutyl, phenyl, optionally substituted with one or more Cl, F, CN, CH 3 , CONH 2 ; pyrazolyl, optionally substituted with CH 3 or CH 2 CH 3 ; oxazolyl, optionally substituted with CH 3 or CH 2 CH 3 ; oxadiazolyl, optionally substituted with CH 3 or CH 2 CH 3 ; thiadiazolyl, optionally substituted with CH 3 , CH 2 CH 3 , or CF 3 ; 2-pyridyl, 3-pyridyl, or 4-pyridyl, each optionally substituted with Cl, F, CF 3 , CN, CONH 2 , CONH(CH 3 ) or CON(CH 3 ) 2 ; pyrazinyl, optionally substituted with CH 3 or CH 2 CH 3 ; pyrimidyl, optionally substituted with OCH 3 ; benzoisoxazolyl; and CO(phenyl), wherein the phenyl is optionally fluorinated.

16. The compound of claim 1 , wherein Ring A is piperazinyl, substituted with one or more substituents independently selected from CH 3 , isopropyl, t-butyl, CH(CH 3 )CF 3 , SO 2 CH 2 CH 3 , SO 2 -isopropyl, cyclopropyl, cyclobutyl, (CH 2 )cyclopropyl, phenyl, optionally substituted with one or more Cl, F, CN, CH 3 , CONH 2 ; pyrazolyl, optionally substituted with CH 3 ; oxazolyl, optionally substituted with CH 3 ; oxadiazolyl, optionally substituted with CH 2 CH 3 ; thiadiazolyl, optionally substituted with CH 3 , or CH 2 CH 3 ; 2-pyridyl, optionally substituted with Cl, F, CF 3 , CN, or CONH 2 ; 3-pyridyl, optionally substituted with CF 3 , CN, CONH 2 , or CON(CH 3 ) 2 ; 4-pyridyl, optionally substituted with CONH 2 ; pyrazinyl, optionally substituted with CH 3 ; pyrimidyl, optionally substituted with OCH 3 ; benzoisoxazolyl; and CO(phenyl), wherein the phenyl is optionally fluorinated.

17. The compound of claim 1 , wherein R is F.

18. The compound of claim 1 , wherein R is CH 3 .

19. The compound of claim 1 , wherein n is 1.

20. A compound, which is:

or a pharmaceutically acceptable salt thereof.

21. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and a pharmaceutically acceptable carrier, excipient or vehicle.